Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in WT, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! Please amend your records accordingly. The old numbers will work until the end of 2017 only!

SynAging will be present at the following meetings in 2017:

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings in 2016:

Press & Publications

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
www.ncbi.nlm.nih.gov/pubmed/28623233

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
promisneurosciences.com/uncategorized/promis-neurosciences-designates-pmn350-second-lead-product-development-alzheimers-disease/

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

Company

SynAging is a contract research organization (CRO),

providing new insights and disease-related understanding of drug candidates (small molecules and biopharmaceuticals), nutraceuticals, and other active substances, activity by deploying neurodegenerative disease models.

SynAging provides:

  • In vitro services
    Investigating single to hundreds of test candidates in primary rodent neurons, human neurons and neuronal cell lines.
  • In vivo services
    Investigating test items in validated behavioral paradigms using acutely induced neurodegenerative rodent models.
  • Ex vivo services
    Quantification of synaptic and neuroinflammatory markers by ELISA or immune histochemistry before and after treatment

SynAging maintains long-term strategic research collaborations for target validation and drug discovery for neurodegenerative diseases.

SynAging’s service team has more than 100 years of combined experience in the field of neurodegenerative disease research. Key staff has published more than 50 peer-reviewed publications.

 

Mission:

Providing clients with misfolded-protein-aggregate-induced phenotypic models in wild type systems to model sporadic neurodegenerative diseases, accelerating drug discovery of symptomatic and disease-modifying therapeutics.